What are Allakos'stock price targets for the next 12 months?
10 brokerages have issued 12 month price objectives for Allakos' shares. Their forecasts range from $17.00 to $218.00. On average, they expect Allakos' stock price to reach $90.36 in the next twelve months. This suggests a possible upside of 1,116.2% from the stock's current price.
Where can I buy Allakos stock?
Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $7.43. How much money does Allakos make?
What is the upside for Allakos'stock?
Their forecasts range from $17.00 to $218.00. On average, they expect Allakos' stock price to reach $90.36 in the next twelve months. This suggests a possible upside of 1,116.2% from the stock's current price.
How much does Allakos make a year?
Allakos has a market capitalization of $403.55 million. The company earns $-153.48 million in net income (profit) each year or ($4.13) on an earnings per share basis. How many employees does Allakos have? Allakos employs 125 workers across the globe.
Is Allakos stock a buy?
Out of 9 analysts, 1 (11.11%) are recommending ALLK as a Strong Buy, 1 (11.11%) are recommending ALLK as a Buy, 6 (66.67%) are recommending ALLK as a Hold, 0 (0%) are recommending ALLK as a Sell, and 1 (11.11%) are recommending ALLK as a Strong Sell. What is ALLK's earnings growth forecast for 2022-2024?
Why did Allakos Stock drop?
In December, Allakos published devastating trial data for its lirentelimab monoclonal antibody treatment for eosinophilic gastrointestinal diseases (EGIDs), and the company's share price has continued to lose ground after its initial, precipitous pullback.
Will Allakos stock go back up?
The 8 analysts offering 12-month price forecasts for Allakos Inc have a median target of 5.50, with a high estimate of 20.00 and a low estimate of 2.50. The median estimate represents a +53.20% increase from the last price of 3.59.
What happen to Allakos?
Allakos (ALLK 21.73%) stock sank 87.5% in December, according to data from S&P Global Market Intelligence. The clinical-stage biotech company's share price plummeted after the publication of disappointing trial data for its key treatment.
Why did ALLK stock crash?
In December, Allakos published devastating trial data for its lirentelimab monoclonal antibody treatment for eosinophilic gastrointestinal diseases (EGIDs), and the company's share price has continued to lose ground after its initial, precipitous pullback.
Should I buy or sell Allakos stock right now?
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell ra...
What is Allakos' stock price forecast for 2022?
10 analysts have issued twelve-month price objectives for Allakos' stock. Their forecasts range from $13.00 to $155.00. On average, they predict Al...
How has Allakos' stock performed in 2022?
Allakos' stock was trading at $9.79 at the beginning of 2022. Since then, ALLK stock has decreased by 68.7% and is now trading at $3.06. View the...
When is Allakos' next earnings date?
Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Allakos .
How were Allakos' earnings last quarter?
Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Friday, May, 6th. The company reported ($3.60) EPS for the quarter, missing anal...
Who are Allakos' key executives?
Allakos' management team includes the following people: Dr. Robert Alexander Ph.D. , CEO & Director (Age 52, Pay $1.39M) Dr. Adam L. Tomasi Ph.D...
Who are some of Allakos' key competitors?
Some companies that are related to Allakos include uniQure (QURE) , TG Therapeutics (TGTX) , Erasca (ERAS) , IGM Biosciences (IGMS) , Organoge...
What other stocks do shareholders of Allakos own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV) , Advanced Mi...
When did Allakos IPO?
(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00...
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
Handelsbanken Fonder AB Buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Sells SVB Financial ..
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
About Allakos
Investment company Handelsbanken Fonder AB (Current Portfolio) buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Alnylam Pharmaceuticals Inc, Fair Isaac Corp, sells SVB Financial Group, Ameresco Inc, Activision Blizzard Inc, Wolfspeed Inc, Teladoc Health Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Handelsbanken Fonder AB..
Headlines
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
Allakos (NASDAQ:ALLK) Frequently Asked Questions
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance
What time do you trade in the pre market?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Allakos stock.
What is Allakos Inc?
Trending Stocks. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices.
Does market cap include convertible securities?
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases.
Historical and forecast chart of Allakos stock
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Allakos Daily Price Targets
The chart below shows the historical price of Allakos stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Allakos stock price can be found in the table below.
Allakos forecast for this year
Forecast target price for 02-24-2022: $ 5.76. Positive dynamics for Allakos shares will prevail with possible volatility of 2.717%.
Allakos information and performance
An downtrend is forecast for this month with an optimal target price of $ 5.68512. Pessimistic: $5.41. Optimistic: $5.98
